tirzepatide constipation side effect Answering all your questions about and its effects on endo!! #endometriosis #tirzepatide #weightloss #pcos #education Managing Constipation on Tirzepatide: Relief

Description

Peker, Y

Advanced dual-hormone mechanism

Why the glucagon receptor changes everything The glucagon component is not just an incremental improvement

Tirzepatide compared to other GLP-1 medications Tirzepatide is one of several GLP-1 receptor agonists available for weight management and metabolic health

MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group